Effects of Dobutamine on Microcirculation, Regional and Peripheral Perfusion in Septic Shock Patients
Information source: Pontificia Universidad Catolica de Chile
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Septic Shock
Intervention: Dobutamine (Drug); Placebo (Drug)
Phase: N/A
Status: Completed
Sponsored by: Pontificia Universidad Catolica de Chile Official(s) and/or principal investigator(s): Glenn Hernandez, MD, Principal Investigator, Affiliation: Pontificia Universidad Catolica de Chile
Summary
The investigators hypothesize that dobutamine is able to revert negative redistribution of
flow by inducing a selective vasodilatory effect on hypoperfused territories, particularly
at the sublingual and gastric mucosa, and at the peripheral tissues.
The investigators designed a randomized, cross-over, placebo-controlled study looking at the
acute physiologic effects of 5 mcg/kg/min fixed-dose of dobutamine on cardiac function,
microcirculation, gastric mucosal, hepatosplanchnic, and peripheral perfusion in septic
shock patients.
Clinical Details
Official title: Effects of Dobutamine on Microcirculation, Regional and Peripheral Perfusion in Septic Shock Patients.
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Change in the perfused vascular density
Secondary outcome: MacrohemodynamicsTransthoracic echocardiography Gastric mucosal perfusion Hepatosplanchnic blood flow Peripheral perfusion Metabolic perfusion assessment
Detailed description:
The investigators hypothesize that dobutamine is able to revert negative redistribution of
flow by inducing a selective vasodilatory effect on hypoperfused territories, particularly
at the sublingual and gastric mucosa, and at the peripheral tissues. Therefore, dobutamine
improves microcirculatory alterations and regional perfusion in septic shock, independent of
its effects on cardiac output.
The relevance of this concept is that it would support a more rational use of dobutamine in
septic shock patients, not only as an inotrope to increase cardiac output, but more
important, as a selective vasodilator aimed at restoring perfusion.
Therefore, the investigators designed a randomized, cross-over, placebo-controlled study
looking at the acute physiologic effects of 5 mcg/kg/min fixed-dose of dobutamine on cardiac
function, microcirculation, gastric mucosal, hepatosplanchnic, and peripheral perfusion in
septic shock patients.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Adult patients (>18 years)
- Septic shock for less than 24 hours
- Arterial lactate > 2. 4 mmol/l
- Mechanical ventilation and pulmonary artery catheter in place
Exclusion Criteria:
- Pregnancy
- Refractory hypotension
- Acute coronary syndrome within the last 3 months
- Previous use of dobutamine during the last 72 hours
- Cardiac index < 2. 5 l/min/m2
- Non-sinus rhythm
- Heart rate >140 BPM
- Anticipated surgery or dialytic procedure during the study period
- Child B or C liver cirrhosis
- Hemoglobin < 8 gr/dl
- Uncontrollable fever > 39ÂșC
Locations and Contacts
Hospital Clinico Universidad Catolica de Chile, Santiago, RM 6510260, Chile
Additional Information
Starting date: August 2010
Last updated: June 25, 2015
|